Skip to content

SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors

Improving Medication Adherence With Adjuvant Aromatase Inhibitor in Women With Breast Cancer: A Randomised Controlled Trial to Evaluate the Effect of Short Message Service (SMS) Reminder

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02524548
Enrollment
244
Registered
2015-08-17
Start date
2015-05-31
Completion date
2020-01-31
Last updated
2020-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Medication Adherence

Keywords

Aromatase inhibitors, Reminder Systems

Brief summary

The purpose of this study is to determine whether weekly SMS reminders are effective in improving medication adherence of adjuvant aromatase inhibitors in women with breast cancer.

Detailed description

This study is a prospective randomised controlled parallel trial of SMS reminder versus standard care to investigate whether SMS reminder improves adherence to oral aromatase inhibitor (AI) therapy amongst women with breast cancer at 1-year follow-up. All subjects will be randomised to receive either SMS reminder or standard care in a 1:1 ratio. Balanced permuted block randomisation will be implemented with random varying of block sizes of 4 or 6. The sample size is estimated based on the primary endpoint of medication adherence (as measured via SMAQ) at 1-year. Assuming that the proportion of medication adherence in the intervention and control groups are 80% and 60% respectively, then based on a 5% significance level and a power of 90%, a minimum sample of 240 subjects (i.e. 120 per group) will be required. Further assuming an attrition rate of 10%, the anticipated trial size is 280 overall. The assessment of medication adherence at 1-year (as measured via SMAQ) between the SMS reminder and control groups will be made using chi-square test. Adjustment for baseline covariate and potential confounders will be made using the logistic regression where appropriate. Other measures of adherence such as the 1-year MPR, PDC and pill count will be compared between treatment arms via the t- test, with adjustment for confounders made via the analysis of covariance (ANCOVA). Natural log transformation will be implemented on the estrone and androstenedione measures to normalise the data. The assessment of secondary outcomes involving the log transformed estrone and androstenedione levels will be made using the analysis of covariance (ANCOVA) to adjust for the respective baseline levels and other potential confounders. Comparison of estradiol levels (defined as \<18.4 versus ≥18.4) between the two arms will be made using chi-square test. The logistic regression analysis will be implemented to adjust for baseline covariate and other potential confounders where appropriate. The assessment of knowledge, attitude, behavior, as well as barrier and facilitating factors between the intervention and control groups will be made using chi-square test, with treatment effect quantified based on odds ratio estimate and its 95% CI. Further adjustment for baseline scores and other potential confounders will be made using the logistic regression where appropriate. Additionally, the investigators will compare the 4 different measures of adherence in a separate paper, to determine which of these provide a more meaningful or reliable information in the local context based on sensitivity analysis. All analyses will be performed according to intention-to-treat using STATA, assuming a two-sided test at the 5% level of significance.

Interventions

Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor for 1 year

Sponsors

Singapore Cancer Society
CollaboratorOTHER
National University of Singapore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Women who have been receiving adjuvant endocrine therapy for at least 1 year, and are continuing to receive adjuvant AI therapy for at least 1 more year. 2. Have cellular phone that can receive text messages. 3. Singaporean or permanent resident who is currently residing in Singapore. 4. Able to give informed consent.

Exclusion criteria

1\. Unable or not willing to comply with study procedures.

Design outcomes

Primary

MeasureTime frameDescription
Medication adherenceOne yearSimplified medication adherence questionnaire (SMAQ)

Secondary

MeasureTime frameDescription
AndrostenedioneOne yearin nmol/L
EstroneOne yearin pg/mL
EstradiolOne yearin pmol/L

Other

MeasureTime frameDescription
Patients' knowledge, attitude, and behavior towards medication adherenceOne yearThe Beliefs about Medicines Questionnaire (BMQ)

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026